In the article beginning on page 1283 in the December 2020 issue, the statement on page 1286 that “No specific reversal agent is currently available for the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban” is incorrect. The corrected sentence should read: “Andexanet alfa is the specific reversal agent for the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban.”

The authors regret this error. The online version and PDF of the article have been corrected.

You do not currently have access to this content.